Focused settings, such as relapsed glioblastoma, neoadjuvant colorectal and breast cancer, and advanced prostate cancer would be ideal for evaluating CXCR4-inhibiting agents in the development and progression of metastases. Here, CXCR4 is linked to breast carcinoma.